کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
6247162 1284514 2015 5 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Emerging Perspectives in TransplantationRenal transplantationEarly or Late Conversion From Tac-BD to Tac-BD in Renal Transplantation: When is the Right Time?
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی عمل جراحی
پیش نمایش صفحه اول مقاله
Emerging Perspectives in TransplantationRenal transplantationEarly or Late Conversion From Tac-BD to Tac-BD in Renal Transplantation: When is the Right Time?
چکیده انگلیسی


- We examined 125 renal transplant patients converted from Tac-BD to Tac-QD.
- Patients converted early and late after transplantation were compared.
- Higher doses and increased dose changes were seen in the early group.
- No difference in renal function, rejection, or graft survival between groups.
- Converting to Tac-QD is safe within the first year after transplantation.

BackgroundIncreasing numbers of renal transplant recipients are converted from Prograf (Astellas Pharma, Tokyo, Japan) (tacrolimus twice daily [Tac-BD]) to Advagraf (Astellas) (tacrolimus once daily [Tac-QD]), but the optimal time for conversion is as yet unclear. This study aimed to investigate the correlation between the time of conversion from Tac-BD to Tac-QD after renal transplant and the dosing requirements, tacrolimus levels, renal function, and clinical outcomes.MethodsSince September 2008, 125 renal transplant patients were converted from Tac-BD to Tac-QD and followed up for 2 years after conversion. Patients were split into early (0 to 12 months) and late (>12 months) conversion groups. Demographics, Tac-QD dose, trough levels, graft function, and patient and graft outcome were prospectively collected.ResultsForty-four patients (35.2%) were converted early (3.82 ± 3.24 months), whereas 81 (64.8%) patients were converted late (77.35 ± 53.71 months). Tac-BD dose before conversion was higher in the early group (8.70 ± 6.34 vs 4.44 ± 2.15 mg) as was the initial Tac-QD dose (8.66 ± 6.20 vs 4.37 ± 2.04 mg, P < .0001), and remained higher for 18 months after conversion, as did the serum tacrolimus trough level levels. Renal function, acute rejection, and patient and graft survival were comparable between the groups.ConclusionsPatients can be safely converted to Tac-QD within the first year post-transplantation, without adverse effects on clinical outcome, despite the higher doses and tacrolimus levels for the first 18 months.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Transplantation Proceedings - Volume 47, Issue 6, July–August 2015, Pages 1741-1745
نویسندگان
, , ,